Genotypic Methods for HIV Drug Resistance Monitoring: The Opportunities and Challenges Faced by China

Author:

Zuo Lulu1ORCID,Peng Ke2,Hu Yihong3,Xu Qinggang1

Affiliation:

1. Institute of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu 212002, China

2. State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China

3. Pathogen Discovery & Big Data Center, CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences; Shanghai 200031, China

Abstract

AIDS is a globalized infectious disease. In 2014, UNAIDS launched a global project of “90-90-90” to end the HIV epidemic by 2030. The second and third 90 require 90% of HIV-1 infected individuals receiving antiretroviral therapy (ART) and durable virological suppression. However, wide use of ART will greatly increase the emergence and spreading of HIV drug resistance and current HIV drug resistance test (DRT) assays in China are seriously lagging behind, hindering to achieve virological suppression. Therefore, recommending an appropriate HIV DRT method is critical for HIV routine surveillance and prevention in China. In this review, we summarized the current existing HIV drug resistance genotypic testing methods around the world and discussed the advantages and disadvantages of these methods.

Funder

State Key Laboratory of Virology

National Natural Science Foundation of China

Publisher

Bentham Science Publishers Ltd.

Subject

Virology,Infectious Diseases

Reference169 articles.

1. UNAIDS. Global AIDS Monitoring 2019 - Indicators for Monitoring the 2016 United Nations Political Declaration on Ending AIDS. 2018. Available from

2. UNAIDS. 90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic 2017. Available from

3. UNAIDS. On the Fast-Track to End AIDS: UNAIDS 2016 - 2021 Strategy 2015. Available from

4. UNAIDS. Available fromtreatment

5. Gupta R.K.; Gregson J.; Parkin N.; HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis. Lancet Infect Dis 2018,18(3),346-355

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3